SCLX
Scilex Holding Company (SCLX)
Healthcare • NASDAQ • $7.82-2.74%
- Symbol
- SCLX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Price
- $7.82
- Daily Change
- -2.74%
- Market Cap
- $55.00M
- Trailing P/E
- N/A
- Forward P/E
- 10.71
- 52W High
- $34.27
- 52W Low
- $3.92
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.79
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel …
Company websiteResearch SCLX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.